Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.67 |
| ▸ | NTRK2 | Q16620 | 7/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924948 | 0.90 | NTRK1 (0.69) | NTRK1NTRK2KDRRETKCNH2 | |
| SCHEMBL3980576 | 0.90 | NTRK1 (0.69) | NTRK1NTRK2KDRRETAURKA | |
| SCHEMBL1924636 | 0.89 | NTRK1 (0.85) | NTRK1NTRK2KDRRETAURKA | |
| SCHEMBL14537222 | 0.88 | NTRK1 (0.67) | NTRK1NTRK2KDRRETKCNH2 | |
| SCHEMBL1925029 | 0.87 | NTRK1 (0.66) | NTRK1NTRK2KCNH2 | |
| SCHEMBL1925611 | 0.86 | NTRK1 (0.71) | NTRK1NTRK2KDRRETAURKA | |
| SCHEMBL4708490 | 0.85 | NTRK1 (0.52) | NTRK1NTRK2KDRAURKAPLK4 | |
| SCHEMBL1925017 | 0.84 | NTRK1 (0.63) | NTRK1NTRK2 | |
| SCHEMBL1924225 | 0.83 | NTRK1 (0.67) | NTRK1NTRK2KCNH2NTRK3 | |
| SCHEMBL1924896 | 0.83 | NTRK2 (0.69) | NTRK1NTRK2KDRRETMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | claimed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | claimed |
| EP-1948664-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | claimed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | claimed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | claimed |
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885KDR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.